Talking KRAS-Targeted Therapy in NSCLC With Dr. Drilon

In our exclusive interview, Alexander Drilon, MD, discusses some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in non–small cell lung cancer.

Welcome to a very special edition of OncLive® On Air! I’m your host today, Caroline Seymour.

OncLive® On Air is a podcast from OncLive, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In today’s episode, sponsored by Amgen, we had the pleasure of speaking with Alexander Drilon, MD, research director of Early Drug Development at Memorial Sloan Kettering Cancer Center, to discuss KRAS-targeted treatment strategies in advanced non–small cell lung cancer.

Approximately 10% to 15% of patients with NSCLC harbor a KRAS G12C mutation, making it an important target in the space. A number of inhibitors had been evaluated in the past, but it was not until the 2019 ASCO Annual Meeting that the first breakthrough reported was AMG 510.

Preliminary results from the phase 1 study showed that of 10 patients with previously treated KRAS G12C-mutant NSCLC, 5 achieved a partial response (PR). At the 2019 World Conference on Lung Cancer, an expanded data set showed that among 23 evaluable patients, the objective response rate was 48%. Thirteen of these patients received the phase 2 dose of 960 mg, and of these patients, 54% achieved a PR.

On September 9, 2019, the FDA granted a fast track designation to the agent for the treatment of patients with previously treated KRAS G12C–mutant metastatic NSCLC, based on these early trial results.

In our exclusive interview, Drilon, discussed some of the historical challenges of targeting KRAS and provided perspective on available and anticipated data with AMG 510 in NSCLC.